Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Chief Medical Officer | January 23, 2025 | January 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PLIANT THERAPEUTICS, INC.
Report date January 23, 2025 · Filed January 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 240,224 |
Reported balance
After 2025-01-23 transaction · row 1
1 source rowRow 1 · 2025-01-23 · Grant · Acquired 45,650 · Balance 240,224 F1: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2035-01-23 | Direct | 91,300 |
Reported balance
After 2025-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-23 · Grant · Acquired 91,300 · Balance 91,300 F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CymaBay Therapeutics, Inc.
Report date March 22, 2024 · Filed March 22, 2024
Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.21 · Expires 2032-03-20 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-22 · Disposition to issuer · Disposed 115,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2024-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-22 · Disposition to issuer · Disposed 14,010 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Tobira Therapeutics, Inc.
Report date November 01, 2016 · Filed November 03, 2016
Section 16 reporting ended · disclosed 2016-11-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2022-02-15 | Direct | 0 |
Reported balance
After 2016-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-01 · Disposition to issuer · Disposed 79,287 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2025-05-15 | Direct | 0 |
Reported balance
After 2016-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.91 · Expires 2026-01-12 | Direct | 0 |
Reported balance
After 2016-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-01 · Disposition to issuer · Disposed 101,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time")
F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"),
F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor.
F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2025 Filed Jan 27, 2025 18:04 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 91,300 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-25-000013 · wk-form4_1738019047.xml · derivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,300 Underlying: Common Stock · 91,300 shares Expires 2035-01-23 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 18:04 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 45,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-25-000013 · wk-form4_1738019047.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,224 F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 18:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 18,478 | $11.20 | $206,973.93 |
DisclosureSEC source: 0001746473-25-000003 · wk-form4_1737586829.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,574 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 18:45 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 12,319 | $11.56 | $142,407.64 |
DisclosureSEC source: 0001746473-24-000129 · wk-form4_1720824309.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,052 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 17:01 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 24,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-24-000119 · wk-form4_1720731654.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,371 F1 · shares: On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 24,063 shares. F2 · balance_after: Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 17:05 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 14,010 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0000950170-24-035468 · ownership.xml · derivative · entry 3 Lefebvre Eric · CIK 0001614741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,010 shares Expires 2034-01-23 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 17:05 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $7.80 | Not disclosed |
DisclosureSEC source: 0000950170-24-035468 · ownership.xml · derivative · entry 2 Lefebvre Eric · CIK 0001614741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2033-01-24 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| March 22, 2024 Filed Mar 22, 2024 17:05 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 115,000 | Not disclosed Strike: $3.21 | Not disclosed |
DisclosureSEC source: 0000950170-24-035468 · ownership.xml · derivative · entry 1 Lefebvre Eric · CIK 0001614741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,000 shares Expires 2032-03-20 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 18:16 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 14,010 | $0.00 Strike: $22.85 | $0.00 |
DisclosureSEC source: 0001062993-24-001418 · form4.xml · derivative · entry 1 Lefebvre Eric · CIK 0001614741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,010 Underlying: Common Stock · 14,010 shares Expires 2034-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2024. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 16:58 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 85,800 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-24-000017 · wk-form4_1706133471.xml · derivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,800 Underlying: Common Stock · 85,800 shares Expires 2034-01-23 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 16:58 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 42,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-24-000017 · wk-form4_1706133471.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,820 F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 17:18 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 10,295 | $17.23 | $177,382.85 |
DisclosureSEC source: 0001746473-24-000002 · wk-form4_1705702729.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,920 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, o between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 20:29 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 22,321 | $18.01 | $401,981.12 |
DisclosureSEC source: 0001209191-23-042831 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,215 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 19:22 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042660 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,536 F1 · shares: On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 43,750 shares. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 19:01 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 11,245 | $26.52 | $298,227.52 |
DisclosureSEC source: 0001209191-23-022374 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,786 F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 18:02 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 21,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021921 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,031 F1 · shares: On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,874 shares. F2 · balance_after: Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 16:33 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001062993-23-001495 · form4.xml · derivative · entry 1 Lefebvre Eric · CIK 0001614741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2023. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003178 · form4.xml · derivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-01-24 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 19:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003178 · form4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,926 F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 67,500 | $34.48 | $2,327,629.50 |
DisclosureSEC source: 0001140361-23-002784 · form4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,926 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 21:32 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 10,887 | $19.10 | $207,967.83 |
DisclosureSEC source: 0001140361-22-046569 · form4.xml · nonDerivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,426 F2 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:32 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 21,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-046569 · form4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,313 F1 · shares: On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,876 shares. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 21:05 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 5,000 | $25.05 | $125,241.00 |
DisclosureSEC source: 0001209191-22-054747 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,437 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2021. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.27, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · balance_after: Includes 1 share of Common Stock acquired by the reporting person pursuant to an employee stock purchase program. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 19:06 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 3,000 | $20.00 | $60,000.00 |
DisclosureSEC source: 0001567619-22-013995 · doc1.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,436 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. F2 · balance_after: Includes 4,356 shares of Common Stock acquired by the reporting person pursuant to an employee stock purchase program. Read SEC document |
| March 21, 2022 Filed Mar 21, 2022 17:40 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001062993-22-008214 · form4.xml · derivative · entry 1 Lefebvre Eric · CIK 0001614741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2032-03-20 F1 · derivative.exercise_date: The option vests as to 1/36 of the underlying shares monthly from March 21, 2022. Read SEC document |
| January 26, 2022 Filed Feb 2, 2022 20:13 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001567619-22-002398 · doc1.xml · derivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 19:52 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 22 | $30.23 | $665.06 |
DisclosureSEC source: 0001209191-21-042577 · doc4.xml · nonDerivative · entry 3 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,080 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 19:52 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 3,728 | $29.43 | $109,718.02 |
DisclosureSEC source: 0001209191-21-042577 · doc4.xml · nonDerivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,102 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.2000 to $29.8500, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 19:52 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 8,750 | $28.62 | $250,438.13 |
DisclosureSEC source: 0001209191-21-042577 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,830 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.2000 to $29.1900, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 19:09 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 1,135 | $39.78 | $45,150.19 |
DisclosureSEC source: 0001209191-21-022161 · doc4.xml · nonDerivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,580 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.72 to $39.84, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 19:09 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 11,365 | $39.38 | $447,527.56 |
DisclosureSEC source: 0001209191-21-022161 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,715 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.72 to $39.70, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 23, 2021 Filed Jan 26, 2021 20:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 73,250 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0000899243-21-003381 · doc4.xml · derivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,250 Underlying: Common Stock · 73,250 shares Expires 2031-01-22 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 20:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 5,712 | $26.98 | $154,109.76 |
DisclosureSEC source: 0000899243-20-034780 · doc4.xml · nonDerivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,080 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.57 to $27.41, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 20:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 6,788 | $26.17 | $177,641.96 |
DisclosureSEC source: 0000899243-20-034780 · doc4.xml · nonDerivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.57 to $26.56, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 14:23 UTC | Tobira Therapeutics, Inc. TBRA · Entity 181299 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 101,000 | Not disclosed Strike: $7.91 | Not disclosed |
DisclosureSEC source: 0001209191-16-148099 · doc4.xml · derivative · entry 3 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,000 shares Expires 2026-01-12 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 14:23 UTC | Tobira Therapeutics, Inc. TBRA · Entity 181299 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0001209191-16-148099 · doc4.xml · derivative · entry 2 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-05-15 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 14:23 UTC | Tobira Therapeutics, Inc. TBRA · Entity 181299 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 79,287 | Not disclosed Strike: $3.51 | Not disclosed |
DisclosureSEC source: 0001209191-16-148099 · doc4.xml · derivative · entry 1 Lefebvre Eric · CIK 0001614741 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,287 shares Expires 2022-02-15 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.